Abstract: Provided is a dexmedetomidine-containing non-aqueous external preparation being capable of suppressing the precipitation of a crystal of dexmedetomidine in the preparation, and having satisfactory transdermal absorbability. The non-aqueous external preparation includes: (A) dexmedetomidine or a salt thereof; (B) an aliphatic alcohol having 10 to 12 carbon atoms; (C) a propylene glycol monoester of a fatty acid having 6 to 16 carbon atoms; (D) an organic acid; and (E) an organic acid salt.

Abstract: The present invention provides a rocuronium preparation with an excellent stability. The rocuronium preparation contains rocuronium and a buffer solution and having an adjusted pH of 3.5 or less (for example, 2.5 to 3.5). The buffer solution may be a citric acid-sodium hydroxide buffer solution, a tartaric acid-sodium hydroxide buffer solution, a potassium hydrogen phthalate-hydrochloric acid buffer solution, a glycine-hydrochloric acid buffer solution, or the like. Such a rocuronium preparation has, for example, after 6-month storage at 40° C., a generation rate of rocuronium-related substance C of 5% or less.

Abstract: Provided is a rocuronium preparation designed to reduce vascular pain to be induced. The rocuronium preparation contains rocuronium and a buffer solution, and has titratable acidity of 100 mEg or less. The buffer solution may be an acetate buffer solution, a citrate buffer solution, a formate buffer solution, a tartrate buffer solution, a phosphate buffer solution, a glycine-hydrochloric acid buffer solution, or a citric acid-phosphate buffer solution.

Abstract: Provided are a method for industrially advantageously producing a highly purified pentapeptide and an intermediate thereof. A compound represented by the following formula (1) or a salt thereof: wherein R1 represents an alkyl group or an aralkyl group.

Abstract: Provided is a patch providing sufficiently high absorbability of dexmedetomidine and less skin irritation. Hydrous adhesive patch comprising dexmedetomidine or a salt thereof and a water-soluble polymer.

Abstract: Provided are a method for industrially advantageously producing a highly purified pentapeptide and an intermediate thereof. A compound represented by the following formula (1) or a salt thereof: wherein R1 represents an alkyl group or an aralkyl group.

Abstract: The present invention provides a rocuronium preparation with an excellent stability. The rocuronium preparation contains rocuronium and a buffer solution and having an adjusted pH of 3.5 or less (for example, 2.5 to 3.5). The buffer solution may be a citric acid-sodium hydroxide buffer solution, a tartaric acid-sodium hydroxide buffer solution, a potassium hydrogen phthalate-hydrochloric acid buffer solution, a glycine-hydrochloric acid buffer solution, or the like. Such a rocuronium preparation has, for example, after 6-month storage at 40° C., a generation rate of rocuronium-related substance C of 5% or less.

Abstract: A disinfectant comprising the following (a), (b), (c) and (d), but no other microbicidal disinfecting agents intended for microbicidal disinfection: (a) 40 to 90% (w/w) of ethanol, isopropyl alcohol or a mixture thereof; (b) 0.1 to 2% (w/w) of lactic acid; (c) 0.01 to 2% (w/w) of citric acid; and (d) 0.001 to 0.1% (w/w) of a zinc-containing compound which releases zinc ion in solution, relative to the whole disinfectant.

Abstract: Provided is a patch providing sufficiently high absorbability of dexmedetomidine and less skin irritation. Hydrous adhesive patch comprising dexmedetomidine or a salt thereof and a water-soluble polymer.

Abstract: Provided is an agent for stabilizing acetaminophen in an aqueous composition, the agent comprising glycine. The agent further comprising at least one kind of sulfurous acid salt selected from the group consisting of sodium sulfite, potassium sulfite and potassium pyrosulfite is more effective. The stabilizing includes preventing precipitation.

Abstract: Provided is a rocuronium preparation designed to reduce vascular pain to be induced. The rocuronium preparation contains rocuronium and a buffer solution, and has titratable acidity of 100 mEg or less. The buffer solution may be an acetate buffer solution, a citrate buffer solution, a formate buffer solution, a tartrate buffer solution, a phosphate buffer solution, a glycine-hydrochloric acid buffer solution, or a citric acid-phosphate buffer solution.

Abstract: The hand hygiene moment measuring system of the present invention includes a subject sensing device (2) to sense a subject's position and posture, a movement sensing device (3) to sense a subject's movement, a storage unit (4) to store particular combinations corresponding to hand hygiene opportunities, and a counter (5) to count a number of times combinations of a sensing information of the subject sensing device, a sensing information of the movement sensing device, and an object position information indicating a position of an object, achieved the combinations stored in the storage unit.

Abstract: A disinfectant comprising the following (a), (b), (c) and (d), but no other microbicidal disinfecting agents intended for microbicidal disinfection: (a) 40 to 90% (w/w) of ethanol, isopropyl alcohol or a mixture thereof; (b) 0.1 to 2% (w/w) of lactic acid; (c) 0.01 to 2% (w/w) of citric acid; and (d) 0.001 to 0.1% (w/w) of a zinc-containing compound which releases zinc ion in solution, relative to the whole disinfectant.

Abstract: An object of the present invention is to provide a medicine for general anesthesia which can prevent and/or alleviate an anesthetic-induced neurological deficit in the brain (preferably in the developing brain). The present invention relates to a medicine which comprises a combination of a general anesthetic and hydrogen and can prevent and/or alleviate an anesthetic-induced neurological deficit in the brain (preferably in the developing brain).

Abstract: A disinfectant comprising the following (a), (b), (c) and (d), but no other microbicidal disinfecting agents intended for microbicidal disinfection: (a) 40 to 90% (w/w) of ethanol, isopropyl alcohol or a mixture thereof; (b) 0.1 to 2% (w/w) of lactic acid; (c) 0.01 to 2% (w/w) of citric acid; and (d) 0.001 to 0.1% (w/w) of a zinc-containing compound which releases zinc ion in solution, relative to the whole disinfectant.

Abstract: A microbicidal and antiseptic composition, which comprises the following (a), (b) and (c): (a) at least one kind of alcohols selected from the group consisting of ethanol and isopropanol; (b) at least one kind of carboxyvinyl polymers selected from the group consisting of polyacrylic acids, polyacrylates, copolymers of polyacrylic acids and polyacrylic acid alkyl esters, and copolymers of polyacrylates and polyacrylic acid alkyl esters; and (c) agar.

Abstract: A disinfectant comprising the following (a), (b), (c) and (d), but no other microbicidal disinfecting agents intended for microbicidal disinfection: (a) 40 to 90% (w/w) of ethanol, isopropyl alcohol or a mixture thereof; (b) 0.1 to 2% (w/w) of lactic acid; (c) 0.01 to 2% (w/w) of citric acid; and (d) 0.001 to 0.1% (w/w) of a zinc-containing compound which releases zinc ion in solution, relative to the whole disinfectant.

Abstract: A microbicidal and antiseptic composition, which comprises the following (a), (b) and (c): (a) at least one kind of alcohols selected from the group consisting of ethanol and isopropanol; (b) at least one kind of carboxyvinyl polymers selected from the group consisting of polyacrylic acids, polyacrylates, copolymers of polyacrylic acids and polyacrylic acid alkyl esters, and copolymers of polyacrylates and polyacrylic acid alkyl esters; and (c) agar.

Abstract: Provided is a novel isoindoline compound of the formula (I): The compound is useful for anesthesia by inducing sedation in a mammal.

Abstract: [Problems] The objective is to provide a new low-toxic drug for external use for intractable diseases, such as erosion, decubitus, and skin ulcer, that prevents cicatrization and reduces iodine accumulation on wound surfaces with sufficiently promoting healing. [Means for solving problem] Preparation of a wound treatment drug for external use containing oily bases and iodine but substantially no white soft sugar, which is a characteristic of the drug of this invention. The invented drug prevents infection through the wound surface due to a sufficient bactericidal effect of iodine, and promotes wound healing, prevents cicatrization and reduces iodine accumulation on the wound surface by maintenance of appropriate moisture in the wound surface due to a moisturizing effect of oily bases.